What You Should Know About Container Closure Integrity Requirements In The Revised EU Annex 1
Source: Lighthouse Instruments
The revised EU Annex 1 contains new requirements for ensuring the container closure integrity (CCI) of sterile pharmaceutical products, causing pharmaceutical companies to reassess their CCI policies for compliance.
Learn in detail how the new requirements of the revised EU Annex 1 may impact your strategy for ensuring CCI of sterile pharmaceutical products. Gain an understanding of the advantages and disadvantages of CCI testing methods and why a science-based holistic approach to ensure good CCI is important. Explore how cold chain storage and transport can impact the CCI of sterile pharmaceutical products.
access the Webinar!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
Lighthouse Instruments
This website uses cookies to ensure you get the best experience on our website. Learn more